1	Activation of the renin-angiotensin-aldosterone system is attenuated in hypertensive compared
2	to normotensive pregnancy
3	
4	<sup>1</sup> Robin Shoemaker*, <sup>2</sup> Marko Poglitsch, <sup>3</sup> Hong Huang, <sup>4</sup> Katherine Vignes, <sup>4</sup> Aarthi Srinivasan,
5	<sup>4</sup> Cynthia Cockerham, <sup>3</sup> Aric Schadler, <sup>3</sup> John A. Bauer, <sup>4</sup> John M. O'Brien
6	
7	<sup>1</sup> Department of Dietetics and Human Nutrition, University of Kentucky, Lexington KY, USA
8	<sup>2</sup> Attoquant Diagnostics GmbH, Vienna, Austria
9	<sup>3</sup> Department of Pediatrics, University of Kentucky, Lexington KY, USA
10	<sup>4</sup> Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of
11	Kentucky, Lexington KY, USA
12	
13	Running Title: Attenuation of the RAAS in hypertensive versus normotensive pregnancy
14	
15 16 17 18 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36	*First and Corresponding Author: Robin Shoemaker, PhD Assistant Professor University of Kentucky Department of Dietetics and Human Nutrition 119 Funkhouser Building Lexington, KY 40306 859-257-1031 Robin.shoemaker@uky.edu

## 37 Abstract

38 Hypertension during pregnancy increases the risk for adverse maternal and fetal outcomes, but 39 mechanisms of pregnancy hypertension are not precisely understood. Elevated plasma renin 40 activity and aldosterone concentrations play an important role in the normal physiologic 41 adaptation to pregnancy. These effectors are reduced in patients with pregnancy hypertension, 42 creating an opportunity to define features of the renin-angiotensin-aldosterone system (RAAS) 43 that are characteristic of this disorder. In the current study, we used a novel LC-MS/MS-based 44 methodology to develop comprehensive profiles of RAAS peptides and effectors over gestation in a cohort of n=74 pregnant women followed prospectively for the development of gestational 45 hypertension and pre-eclampsia (HYP, n=27) versus remaining normotensive (NT, n=47). In NT 46 47 pregnancy, the plasma renin activity surrogate, (PRA-S, calculated from the sum of [angiotensin 48 I] + [angiotensin II) and aldosterone concentrations significantly increased from first to third 49 trimester, accompanied by a modest increase in concentrations of angiotensin peptide 50 metabolites. In contrast, in HYP pregnancies PRA-S and angiotensin peptides were largely 51 unchanged over gestation, and third trimester aldosterone concentrations were significantly 52 lower compared to NT pregnancies. Results indicate that the predominate features of 53 pregnancies that develop HYP are stalled or waning activation of the RAAS in the second half of 54 pregnancy (accompanied by unchanging levels of angiotensin peptides) and attenuated 55 secretion of aldosterone.

56

57

Keywords: angiotensin, maternal, pregnancy hypertension, biomarkers, mass spectrometry,
 aldosterone

60

# 62 **1. Introduction**

63 New onset hypertension during pregnancy (gestational hypertension or pre-eclampsia) affects 64 5-10% of pregnancies, and the prevalence in the United States is rising[1]. Development of 65 hypertension during pregnancy is associated with long-term health risks for both the mother and 66 the offspring[2], and increases maternal risk for cardiovascular diseases later in life[3, 4]. 67 Knowledge of mechanisms underlying perinatal hypertension could lead to improved strategies 68 for the treatment and/or management of hypertension during pregnancy [5, 6]. 69 The renin angiotensin aldosterone system (RAAS) is a master regulator of blood 70 pressure and fluid homeostasis in pregnant and non-pregnant states[7, 8]. Activity of the RAAS is initiated by the enzymatic cleavage of a ten-amino acid peptide, angiotensin I (Ang I) from the 71 72 N-terminus of angiotensinogen (AGT) by the enzyme renin in a highly regulated reaction. The 73 rate of Ang I formation in plasma, also called plasma renin activity (PRA), is determined by the 74 concentrations of active renin and AGT, where renin is rate-limiting. Ang I serves as a substrate 75 for angiotensin-converting enzyme (ACE), resulting in the formation of angiotensin II (Ang II), 76 the primary effector molecule of the RAAS. The concentration of active Ang II is controlled via 77 negative feedback on renin [9], and by metabolism at the n- or c-terminal by amino- and carboxy 78 peptidases in plasma, where the latter is considered to be a counter-regulatory arm of the 79 RAAS. Cleavage of Ang II by angiotensin-converting enzyme 2 (ACE2) generates angiotensin-80 1-7(Ang 1-7)[10], a peptide with purported vasodilatory and other counter-effects to Ang II[11]. 81 The classical effects of Ang II are mediated through the Ang II type 1 (AT<sub>1</sub>) receptor, and 82 include vasoconstriction, activation of the sympathetic nervous system, and stimulation of aldosterone release from the adrenal cortex[12, 13]. Outside of pregnancy, excess effects of 83 Ang II and aldosterone are associated with inflammation, fibrosis, and endothelial 84 85 dysfunction[14, 15], and abnormal function of the counter-regulatory arm of the RAAS has been 86 described in many cardiovascular [16, 17], renal[18], and infectious disease states (i.e. COVID-87 19)[19].

88 In healthy pregnancy, there is pronounced activation of the RAAS, where PRA and aldosterone concentrations are increased compared to non-pregnant states[20-22]. 89 90 Upregulation of renin activity and aldosterone secretion play key roles in physiologic adaptations 91 to healthy pregnancy, such as promoting water and sodium reabsorption sufficient to support 92 the demand for a 40-50% expansion in blood volume[8, 23, 24]. In contrast, numerous studies 93 have demonstrated that pregnancies with pre-eclampsia or gestational hypertension have lower 94 plasma renin activity and lower aldosterone concentrations compared to normotensive 95 pregnancies, [21, 25-27]. Limited studies suggest the alternative RAAS may also play a role in 96 pregnancy, and that alterations in these components, e.g. Ang-1-7 and/or ACE2, are associated with pre-eclampsia and small-for-gestational age infants[28-30]. The course of RAAS activity 97 over the course of gestation is not precisely understood in either normal or hypertensive 98 99 pregnancy[23, 31]. Understanding key deviations in the normal activity of the RAAS in 100 pregnancy could lead to improved detection or management of gestational hypertension and/or 101 pre-eclampsia.

RAS Fingerprint<sup>™</sup> is novel. liquid chromatography-tandem mass spectrometry (LC-102 103 MS/MS)-based methodology for simultaneous quantification of multiple components of the RAAS in a single sample. Outside of pregnancy, recent studies have utilized RAS Fingerprint<sup>™</sup> 104 105 (or RAS profiling) to generate a biochemical "snapshot" of RAAS activity reflective of disease 106 state in patients with hypertension[32], heart failure[33, 34], and other diseases[35, 36]. In the 107 current study, we used RAS Fingerprint to quantify key effectors (angiotensin peptides and 108 aldosterone) of the RAAS in a cohort of women followed prospectively for the development of 109 gestational hypertension and pre-eclampsia. Our objective was to define prominent features of 110 RAAS activity associated with the development of pregnancy hypertension.

111

## 113 2. Methods and Materials

### 114 Study Population

115 This is a secondary analysis of n=74 pregnant individuals enrolled in an ongoing study at the 116 University of Kentucky. All subjects gave informed consent to participate in the study, which was 117 approved by the University of Kentucky Institutional Review Board, and all study 118 procedures/methods were performed in accordance with relevant guidelines and regulations. 119 The cohort is comprised of pregnant individuals without pre-pregnancy hypertension, but 120 otherwise meeting the following clinical risk factors for pre-eclampsia[37], where inclusion in the 121 study were more than one of the following clinical risk factors: history of preterm preeclampsia, type 1 or 2 diabetes, renal or autoimmune disease; or more than two of the following clinical risk 122 factors: nulliparity, obesity (BMI > 30), family history of pre-eclampsia, Black race, lower income, 123 124 age 35 or older, previous pregnancy with small birth weight or adverse outcome, or in-vitro 125 conception. Patients not meeting these criteria were recruited as controls. Exclusion criteria 126 included age less than 18 or greater than 45 years, multifetal gestation, history of allergy to 127 aspirin, gastrointestinal bleeding, severe peptic ulcer or liver dysfunction, patients on 128 anticoagulant medications, and women with anomalous fetus. 129 Study Design and Groups 130 Pregnant women between 18 and 45 years of age in the first trimester of pregnancy were 131

recruited at the time of their routine prenatal visits or ultrasound appointments in the first trimester screening and followed prospectively for the development of pre-eclampsia, gestational hypertension, and related pregnancy outcomes. Patients were treated according to standard clinical guidelines and data collected as part of routine clinical care. Demographic information was collected upon enrollment. Clinical data and maternal blood were collected at routine visits by trained study personnel at the first (11-16 weeks) and third (28-32 weeks) trimesters of pregnancy, and outcomes were recorded at delivery. Blood pressure was measured following the American Heart Association Guidelines[38], and was determined as the
average of two consecutive measurements per arm assessed in a seated, resting position by
one observer. Clinical data and outcomes were obtained from electronic medical records
(EMR), and input into a REDcap database by study personnel. Maternal blood was collected
into red-top serum tubes and rested at room temperature for 60 minutes followed by
centrifugation, transfer into 200 uL single-use aliquots, and barcoding. Samples were stored at 80°C until analysis.

146 Development of pre-eclampsia or gestational hypertension was the primary endpoint. 147 Pregnancy outcomes were determined after delivery by trained clinical staff. Pre-eclampsia was diagnosed according to guidelines by the American College of Gynecologists[39]: either systolic 148 149 blood pressure (SBP) or diastolic blood pressure (DBP) greater than 140 or 90 mmHg, 150 respectively, measured at least four hours apart after 20 weeks gestation, and one of the 151 following: proteinuria of 300 mg in 24 hours or a urine to protein creatinine ratio = 0.3, elevated 152 serum creatine greater than 1.1 mg/dL, liver function tests (AST/ALT) double the upper limits of 153 normal, platelet counts of <100,00/microliter, flash pulmonary edema, or neurologic features 154 including blurry vision or headaches not relieved with medication. Gestational hypertension was 155 diagnosed as either SBP or DBP greater than 140 or 90 mmHg, respectively, after 20 weeks 156 gestation in women with previously normal blood pressure[39]. The following adverse outcomes 157 were also recorded: gestational diabetes, small for gestational age (defined as fetal weight below the 10<sup>th</sup> percentile), postpartum hemorrhage, preterm premature rupture of membranes 158 159 (PPROM), pre-term labor or pre-term delivery (<34 weeks), presence of polyhydramnios, or fetal 160 death.

In the current study, patients were grouped for analysis based on whether they met the primary endpoint of either pre-eclampsia or gestational hypertension (HYP, n=27), or remained normotensive (NT, n=47). We then investigated differences in measured serum components of

the RAAS over gestation (in the first versus third trimester) and at each time point among NTand HYP groups.

166

167 Quantification of angiotensin peptides, aldosterone, and equilibrium-based biomarkers PRA-S, ACE-S, and the aldosterone to Ang II ratio (AA2-R) in serum using RAS Fingerprint<sup>TM</sup>. 168 169 Serum concentrations of six angiotensin peptides (Ang I, Ang II, Ang III, Ang IV, Ang-1-5, and 170 Ang-1-7) and aldosterone were quantified by LC-MS/MS following a controlled ex vivo 171 equilibration (i.e. equilibrium analysis) that has been previously described[40-43]. Equilibrium 172 analysis generates a "snapshot" of RAAS activity in a sample that reflects the biochemical features of the circulating RAAS, based on the principle that all components required to 173 174 generate angiotensin metabolites in vivo are present in plasma. Briefly, serum samples were 175 incubated at 37 °C for one hour to generate a controlled equilibrium, followed by stabilization 176 through addition of an enzyme inhibitor cocktail. Samples were spiked with stable isotope-177 labeled internal standards at 200 pg/mL for each angiotensin metabolite. The samples were 178 subjected to C-18-based solid-phase-extraction, followed by LC-MS/MS analysis using a 179 reversed-phase analytical column (Acquity UPLC C18, Waters, Milford, Massachusetts, USA) 180 operating in line with a Xevo TQ-S triple guadruple mass spectrometer in multiple reaction 181 monitoring mode (Waters, Milford, Massachusetts, USA). Internal standards were used to 182 correct for peptide recovery of the sample preparation procedure for each analyte in each 183 individual sample. Analyte concentrations were determined using software 184 (MassLynx/Target/Lynx, Waters, Milford, Massachusetts, USA) via integration of the total ion 185 chromatogram obtained from a sum of quantifier transitions that have been optimized for 186 sensitivity and specificity, and integrated signals exceeded a signal-to noise ratio of 10. Analyte 187 concentrations were determined via linear calibration and reported in pmol/L. Batch 188 performance is evaluated based on calculated levels of calibrator and quality control samples (must be within 15% of nominal concentration); lowest calibrator (lower limit of quantification -189

190 LLOQ) must be within 20% of nominal concentration; at least 67% of all guality control and 191 calibrators must comply. The lower limits of quantification (LLOQs) for each peptide were: 192 angiotensin I: 5 pmol/L; angiotensin II: 4 pmol/L; angiotensin III: 4 pmol/L; angiotensin IV: 2 193 pmol/L; angiotensin-(1-5): 2 pmol/L; angiotensin-(1-7): 3 pmol/L, and aldosterone: 13 pmol/L. 194 For values below the LLOQ, means for each analyte and calculation of equilibrium-based 195 biomarkers were calculated using half the LLOQ[43]. 196 Equilibrium concentrations of Ang I, Ang II, and aldosterone were used to calculate 197 biomarkers reflecting PRA, ACE activity, and the aldosterone to Ang II ratio (AA2-R), as 198 previously described[32, 41]. The plasma renin activity surrogate (PRA-S) was calculated from 199 the sum of the equilibrium concentrations of Ang I and Ang II ([egAng I] + [egAng I] (pmol/L); the 200 surrogate for ACE activity (ACE-S) was calculated from the ratio of the equilibrium 201 concentrations of Ang II to Ang I ([eqAng II] / [eqAng I] (pmol/L/pmol/L); the aldosterone to Ang 202 II ratio (AA2-R) was calculated by diving aldosterone concentrations by equilibrium 203 concentrations of Ang II ([Aldosterone] / [eqAng II] (pmol/L/pmol/L). PRA-S, ACE-S, and AA2-R 204 have been utilized as biomarkers of the RAAS that correlate with clinical parameters and/or 205 predict outcomes in numerous studies, including in humans with hypertension and/or primary 206 aldosteronism[32, 44-46], heart failure[33, 43, 47], COVID-19[48, 49], and others[50, 51]. 207 208

209 Statistical Analysis

Statistical analyses were performed via GraphPad Prism version 9.5.1 (San Diego, CA, USA) and SPSS Statistics version 24 (IBM, Armonk, NY). All data were assessed for normality, and the appropriate parametric/nonparametric tests used. Clinical and demographic data were analyzed for between-group differences (NT versus HYP), where continuous variables were analyzed using paired t-tests, and categorical variables were analyzed using chi-square or Fisher's exact test. For serum components of the RAAS, Mann-Whitney tests were applied for

- between-groups analysis at each time point in independent samples, and within-group changes
- 217 from first to third trimester were determined using Wilcoxon matched-pairs signed rank tests. A
- 218 p-value less than 0.05 was considered statistically significant.
- 219
- 220
- 221 **3. Results**

222 Subject characteristics. Paired clinical data and biological samples from first and third trimester visits were obtained for 74 women between April 2019 and May 2020. The cohort 223 224 demographics, clinical characteristics, and outcomes are described in Table 1. The cohort was 225 primarily Caucasian, with Black, Hispanic, and mixed-race individuals distributed fairly equally among groups. The HYP group had a slightly greater risk profile compared to NT, with more 226 227 patients being primiparous, having a previous pre-eclamptic pregnancy, having type 1 diabetes, 228 and taking aspirin for the prevention of pre-eclampsia. The NT group contained slightly more 229 patients with type 2 diabetes, and with renal or autoimmune disease. First trimester BMI was 230 significantly greater in HYP compared to the NT, as was first and third trimester SBP and DBP, although only four patients in the HYP received hypertension treatment. Duration of gestational 231 was significantly shorter in HYP versus NT groups. 232

The HYP group was comprised of twenty-three patients who developed gestational hypertension and six patients that developed pre-eclampsia. Both NT and HYP patients experienced adverse outcomes such as gestational diabetes, PPROM, polyhydramnios, and postpartum hemorrhage. Slightly more HYP than NT patients developed gestational diabetes, but no HYP patients had IUGR or pre-term labor/delivery, compared to two and three, respectively, in the NT group.

239

241

#### 242 Table 1. Patient demographics and clinical characteristics of women that developed gestational

243 hypertension or pre-eclampsia (HYP) in pregnancy or remained normotensive (NT).

Parameter	NT N=47	HYP N=27
Patient Demographics, n (%)		
Race		
Caucasian	33 (70)	20 (74)
Black or African American	7 (15)	4 (15)
Hispanic	6 (13)	2 (7)
Asian	1 (2)	0
Mixed race	0	1 (4)
Primiparous	19 (40)	14 (52)
Previous pre-eclampsia	6 (13)	8 (30)
Type 1 DM	7 (15)	9 (33)
Type 2 DM	5 (11)	2 (7)
Renal disease	1 (2)	0
Autoimmune disease	7 (15)	0
Medications		
Aspirin	22 (47)	18 (67)
Labetalol or Nifedipine	0	4 (15)
Clinical Characteristics, mean <u>+</u> S	SD	
Age, years	30 <u>+</u> 6	28 <u>+</u> 6
BMI (1 <sup>st</sup> trimester), kg/m <sup>2</sup>	29 <u>+</u> 7	32 <u>+</u> 8 <sup>#</sup>
SBP, mmHg		
1 <sup>st</sup> Trimester	113 <u>+</u> 11	122 <u>+</u> 9 <sup>###</sup>
3 <sup>rd</sup> Trimester	115 <u>+</u> 9	126 <u>+</u> 10 <sup>####</sup>
DBP, mmHg		
1 <sup>st</sup> Trimester	73 <u>+</u> 8	80 <u>+</u> 6 <sup>###</sup>
3 <sup>rd</sup> Trimester	73 <u>+</u> 6	81 <u>+</u> 6 <sup>####</sup>
Gestational age at delivery, weeks	38.6 <u>+</u> 1.5	36.8 <u>+</u> 1.6 <sup>####</sup>
Outcomes, n (%)		
Gestational hypertension	0	23 (85)
Pre-eclampsia	0	6 (22)
Gestational diabetes	3 (6)	4 (15)
PPROM	3 (6)	1 (4)
Polyhydramnios	4 (9)	2 (7)
IUGR	2 (5)	0
Pre-term labor or delivery	3 (6)	0
Postpartum hemorrhage	7 (15)	4 (15)

Table 1. Demographics, clinical characteristics, and outcomes in NT and HYPpregnancies. \*, P<0.05; \*\*\*\*, P<0.001; \*\*\*\*\*, P<0.0001 analyzed by *t*-test. 244

- 246 Attenuated activation of the classical RAAS over gestation in pregnancies that develop
- 247 hypertension versus remaining normotensive.
- 248 We used RAS Fingerprint with equilibrium analysis to quantify angiotensin peptides, aldosterone
- 249 concentrations, and biomarkers in serum of pregnant women in the first and third trimester of
- pregnancy. Table 2 list the median and IQR for all measured and calculated components of the
- 251 RAAS in the cohort in general, most components of the RAAS were significantly increased
- over gestation in NT, but not HYP, and tended to be lower in HYP versus NT in the third
- 253 trimester.
- 254

## Table 2. Serum concentrations of RAAS components in normotensive (NT) and hypertensive (HYP) groups in the first and third trimesters of pregnancy.

RAAS Component	NT	HYP	P value <sup>®</sup>
•	N=47	N=20	
Ang I, pmol/L			
1 <sup>st</sup> Trimester	72.7 (45.9 – 112.1)	61.6 (36.2 – 104.1)	0.645
3 <sup>rd</sup> Trimester	115.6 (69.2 – 172.7)	71.6 (51.2 – 145.1)	0.080
Ang II, pmol/L			
1 <sup>st</sup> Trimester	165.3 (110.5 – 197.0)	143.9 (76.3 – 211.7)	0.404
3 <sup>rd</sup> Trimester	180.9 (130.8 – 290.2) <sup>*</sup>	141.9 (87.8 – 244.5)	0.053
Ang III, pmol/L			
1 <sup>st</sup> Trimester	4.3 (2.0 – 9.2)	2.0 (2.0 – 7.3)	0.602
3 <sup>rd</sup> Trimester	5.9 (2.0 – 10.1)	2.0(2.0-4.9)	0.012
Ang IV, pmol/L			
1 <sup>st</sup> Trimester	8.6 (5.3 – 12.9)	5.8 (3.4 – 10.1)	0.107
3 <sup>rd</sup> Trimester	10.1 (5.2 – 14.0)	7.4 (4.6 – 11.9)	0.149
Ang-1-5, pmol/L			
1 <sup>st</sup> Trimester	5.3 (3.4 – 7.8)	4.3 (3.0 – 8.3)	0.571
3 <sup>rd</sup> Trimester	7.7 (5.3 – 10.9)**	5.2 (3.3 – 8.2)	0.084
Aldosterone, pmol/L			
1 <sup>st</sup> Trimester	386.1 (226.2 – 626.2)	290.2 (181.3 – 791.0)	0.680
3 <sup>rd</sup> Trimester	970.5 (468.3 – 1586.0)****	492.5 (260.3 - 826.9)	0.003
PRA-S, pmol/L			
1 <sup>st</sup> Trimester	243.2 (157.5 – 309.1)	194.3 (126.8 – 341.7)	0.426
3 <sup>rd</sup> Trimester	307.9 (214.7 – 474.8)***	223.7 (143.4 – 343.2)	0.067
ACE-S, pmol/L / pmol/L			
1 <sup>st</sup> Trimester	2.16 (1.83 – 2.98)	2.27 (1.79 – 3.21)	0.703
3 <sup>rd</sup> Trimester	1.78 (1.30 – 2.08)****	1.83 (1.45 – 2.41)**	0.534
Aldosterone-Ang II ratio			
(AA2-R), pmol/L / pmol/L			
1 <sup>st</sup> Trimester	2.07 (1.63 – 3.33)	2.25 (0.90 – 4.67)	0.929
3 <sup>rd</sup> Trimester	4.25 (3.20 – 7.71)****	3.38 (2.04 – 6.27)	0.161

257

- Table 2. Concentrations of angiotensin (Ang) peptides, aldosterone, and the biomarkers
- 259 **PRA-S, ACE-S, and AA2-R at equilibrium determined by liquid chromatography with**
- tandem mass spectrometry (LC-MS/MS). Data are median and interquartile range (IQR). @,
- NT versus HYP within trimester, analyzed by Mann-Whitney test. \*, P<0.05, \*\*, P<0.01, \*\*\*,
- 262 P<0.001, \*\*\*\*, P<0.0001 for third trimester vs first trimester within group analyzed by Wilcoxon
- signed rank test. Abbreviations: PRA-S: surrogate biomarker for plasma renin activity,
- 264 calculated from ([Ang I] + [Ang II]); ACE-S: surrogate biomarker for ACE activity, calculated from
- 265 ([Ang II] / [Ang I]).

As previous studies of pregnancy indicated that classical biomarkers for activation of the

268 RAAS, PRA (or direct renin concentration) and plasma aldosterone concentrations (PAC), are

reduced in gestational hypertension or pre-eclampsia[25, 27, 52], we examined PRA-S and

270 aldosterone concentrations generated using RAS Fingerprint in our cohort of NT and HYP

271 pregnancies (Figure 1). PRA-S was significantly increased from the first to third trimester in

pregnancies that remained NT (P<0.001) with a median percent increase of 31% (Figure 1A,

1C). In contrast, PRA-S was not statistically increased in pregnancies that developed HYP



274 (p=0.889), and the median percent change in PRA-S over gestation in the HYP group was zero 275 (Figure 1A, 1C). Median values for PRA-S were not different between NT and HYP at either the 276 first or third trimester, although there was a trend toward a lower PRA-S in HYP versus NT in 277 the third trimester (p=0.067; Figure 1A, Table 2). Similarly, serum aldosterone concentrations 278 significantly increased over gestation in the NT group (P<0.0001), with a median percent increase of 135%. In HYP, aldosterone rose by 57%, although the change over gestation was 279 280 not significant (p=0.141), and third trimester concentrations of aldosterone were significantly lower in HYP versus NT (P<0.01; Figure 1B, 1D, Table 2). 281

282

284	Figure 1. RAS Fingerprint-generated biomarkers for activation of the classical RAAS in
285	normotensive versus hypertensive pregnancy. A) PRA-S, a surrogate for plasma activity
286	calculated from the sum of the equilibrium concentrations of Ang I and Ang II, and B)
287	aldosterone concentrations in the first and third trimesters of pregnancies that developed
288	hypertension after 20 weeks gestation (HYP, n=27) and those that remained normotensive (NT,
289	n=47). PRA-S and aldosterone levels were not different among NT and HYP in the first
290	trimester, but increased over gestation only in the group that remained NT. Data are median,
291	95th confidence intervals (CI). ***, P<0.001, and ****, P<0.0001 for within-group increase from
292	first to third trimester analyzed by Wilcoxon matched-pairs signed rank tests. ##, P<0.01
293	compared to NT using Mann-Whitney test. The percent change from first to third trimester in
294	C)PRA-S and D) aldosterone concentrations in NT and HYP patients. The percent increase
295	over gestation in PRA-S and aldosterone was significantly lower in pregnancies that developed
296	HYP compared to NT. Data are median, 95th CI of the percent change for each biomarker over
297	pregnancy in NT and HYP groups. #, P<0.05 compared to NT using Mann-Whitney test.
298	
299	
300	Metabolism of Ang II and activation of the counter-regulatory RAAS in NT and HYP
301	pregnancies.
302	We quantified angiotensin metabolites upstream (Ang I) and downstream (Ang III and Ang IV,
303	generated via n-terminal metabolism; and Ang-1-5 and Ang-1-7, generated via c-terminal
304	metabolism) from Ang II (Figure 2A-D, Table 2). In NT, Ang II concentrations were only
305	modestly increased across gestation (P<0.05), although Ang I formation was robustly increased
306	across pregnancy (P<0.0001; Figure 2A, 2B, Table 2). In the HYP group, Ang II concentrations
307	were not increased at all (p=0.594), but concentrations of Ang I were (non-significantly)

308 increased over gestation (p=0.052; Figure 2A, 2B, Table 2). There was a relative decrease in Ang II to Ang I over gestation, reflected by a decrease in ACE-S, evident in both NT and HYP 309 groups (Table 2). There was a relative increase in aldosterone concentrations relative to Ang II 310 311 (AA2-R) over gestation in NT (P<0.010) but not HYP patients (p=0.141, Table 2). 312 Metabolism of Ang II was assessed by examining the concentrations of n- (sum of the 313 concentrations of Ang III and Ang IV) and c-terminal metabolites (sum of the concentrations of 314 Ang-1-5 and Ang-1-7), where c-terminal metabolites are reflective of activity of the counter-315 regulatory arm of the RAAS[25]. Concentrations in pmol/L of n- and c-terminal metabolites of Ang II were 10-fold lower than Ang II and Ang I concentrations in both NT and HYP groups 316 317 (Figure 2B, 2C, Table 2). Concentrations of Ang-1-7 were below the LLOQ in most patients in 318 the NT group (detected in only 7 and 16 patients in the first and third trimester, respectively), 319 and in the HYP group (detected in only 7 and 9 patients in the first and third trimester, 320 respectively), so median values with IQR for this analyte were less than the LLOQ and not listed 321 in Table 2. Half the value of the LLOQ (a concentration of 1.5 pmol/L) in those samples with 322 Ang-1-7 concentrations below the LLOQ was used to calculate the sum of c-terminal peptides. 323 The concentrations of c- and n-terminal metabolites were not different in NT versus HYP in the 324 first or third trimester (Figure 2C, 2D), but in the NT group, the concentration of c-terminal 325 metabolites significantly increased over gestation (Figure 2D).





analyzed via Mann-Whitney. \*\*, P<0.01 within-group increase from first to third trimester</li>
 analyzed by Wilcoxon matched-pairs signed rank tests.

338

## 339 4. Discussion

Previous studies have demonstrated that the RAAS is suppressed in pregnancies with 340 341 pregnancy hypertension, but deviations in the activity of the RAAS compared to normotensive 342 pregnancy have not been comprehensively described. We used RAS Fingerprint to quantify 343 multiple angiotensin metabolites and biomarkers of the RAAS over gestation in pregnant women 344 with or without pregnancy hypertension. The main results from this study, the first to report LC-MS/MS-based RAAS profiles in a prospective study of pregnancy hypertension, are 1) a marked 345 346 increase across gestation was evident in PRA-S, and especially aldosterone concentrations, in 347 NT pregnancy, but 2) not in those that developed HYP, where PRA-S was largely unchanged 348 after the first trimester of pregnancy, and third trimester aldosterone concentrations were 349 significantly lower than the NT group; 3) the increase in aldosterone secretion across gestation 350 was proportionally greater than the change in PRA-S or Ang II in both groups, with a more 351 robust effect in the NT group; and 4) c- and n-terminal metabolites, present in low 352 concentrations in both groups, generally increased over gestation in the NT but the HYP group. 353 Taken together, these findings indicate that normotensive pregnancy is associated with a 354 sustained increased in Ang I (and to a lesser degree, Ang II) concentrations over gestation, 355 accompanied by a marked elevation in aldosterone concentrations and moderate increase in 356 alternative RAAS metabolites. The predominate features of pregnancies that develop HYP are 357 stalled or waning activation of the RAAS in the second half of pregnancy (accompanied by 358 unchanging levels of angiotensin peptides) and attenuated secretion of aldosterone. 359 The comprehensive RAAS profiles generated in our study agree with previous studies

reporting low renin and aldosterone levels in normal and hypertensive pregnancy, and extend
 them to include detailed activity of angiotensin peptide metabolites over gestation. PRA and

362 aldosterone concentrations are progressively increased with pregnancy, and can exceed nonpregnant levels by 2-3 fold[26, 52]. PRA is increased early in gestation [53], where aldosterone 363 364 concentrations peak in the third trimester [54]. In pregnancies that develop hypertension, some 365 studies have shown that PRA is initially elevated as in normotensive pregnancy, but fails to 366 increase over gestation or decreases to non-pregnant levels[25]. Several studies have 367 demonstrated that, aldosterone concentrations, although reduced compared to normotensive, 368 still rise to some degree over pregnancy, even when PRA is declining[25, 26]. These studies are 369 consistent with our observations, where PRA-S and aldosterone increased over gestation only 370 in the NT group, but aldosterone remained elevated in in the HYP group. Our study did not contain a non-pregnant group for comparison, but reported values of RAAS biomarkers in non-371 372 pregnant cohorts generated with the same LC-MS/MS-based methodology are available. The 373 median and IQR reported for PRA-S and Ang II in a cohort of 77 individuals with hypertension 374 was 165.6 (80.6-328.3) pmol/L and 100.9 (56.3-227.0) pmol/L, respectively[32]. These values 375 are substantially lower than PRA-S and Ang II values reported here in the third trimester of the 376 HYP group, suggesting that RAAS activity was still higher compared to non-pregnant state. 377 Because pre-eclampsia is associated with lower plasma volume [54], suppression of the 378 RAAS is somewhat paradoxical. In longitudinal studies of pregnancies that developed 379 gestational hypertension or pre-eclampsia, downward trending of PRA levels over pregnancy 380 correlated with the onset of high blood pressure [25, 26, 55]. In our study, patients that 381 developed HYP failed to increase RAS components over pregnancy, and had generally lower 382 concentrations of angiotensin peptides in the third trimester. Downregulation of renin activity 383 with disease course suggests a compensatory response to high blood pressure[55], rather than a primary event in the pathogenesis of the disease. An additional explanation for low activation 384 385 of the RAAS in hypertensive pregnancies could be reduced concentration or availability of 386 AGT[56], the substrate for renin. Langer et al previously made the observation that first trimester

Ang I levels were low compared to Ang II (similar to our study), and suggested that Ang II synthesis was not limited by renin, but rather perhaps by AGT [52].

389 Historical studies by Gant et al demonstrate that normotensive pregnancies become 390 refractory to the pressor effects of Ang II, presumably for protection against vasoconstrictive 391 effects of Ang II, where pregnancies that develop hypertension progressively lose this response 392 over the second half of pregnancy [57]. This suggests factors impacting AT<sub>1</sub> receptor signaling 393 in pregnancy, such as presence or absence of AT<sub>2</sub> receptors[58], metabolic 394 derangements{34658252}, or AT<sub>1</sub> autoantibody-binding might facilitate negative cellular effects 395 of Ang II (promotion of inflammation[59] or renal[60]), that lead to the progression of hypertension. In our cohort, blood pressure was elevated in HYP compared to NT in the first 396 397 trimester, suggesting the presence of underlying vascular dysfunction in this group, potentially 398 caused by previous pre-eclampsia or type 1 diabetes exhibited in this group.

399 Factors contributing to aldosterone secretion in hypertensive pregnancy are complex. 400 Previous studies reported that aldosterone concentrations in pregnancy exceeded those 401 expected on the basis of renin levels [57]. In our study, aldosterone concentrations relative to 402 Ang II were significantly increased over gestation only in NT groups, but HYP pregnancies still 403 had elevated aldosterone compared to non-pregnant cohorts[32] in the second half of 404 pregnancy, despite no sustained activation of the RAAS. These data suggest non-Ang II 405 stimulation of aldosterone is a feature of both normotensive and hypertensive pregnancy, but 406 the possibility of altered sensitivity of  $AT_1$  receptors to Ang II in the adrenal cortex in one group 407 compared to another is not excluded. Purported non-angiotensin stimulants of aldosterone in 408 pregnancy include ACTH, where ACTH simulated aldosterone not only in normotensive but also 409 hypertensive pregnancies[61], and VEGF [62]. In pre-eclampsia, the presence of circulating 410 factors such as the VEGF receptor binding splice variant, sFlts-1, and AT<sub>1</sub>-autoantibodies, may 411 impair aldosterone synthesis or release[63]. In addition, aldosterone concentrations could be 412 suppressed by excess sodium in pre-eclampsia resulting from activation of epithelial sodium

channels (ENaC)[64]. Notably, gain of function variants in aldosterone synthase (CYP11B2)
were preferably present in normotensive versus pre-eclamptic pregnancies, suggesting an
evolutionary basis for an active mineralocorticoid receptor system to protect against preeclampsia[65].

417 Enhanced concentrations of Ang-1-7 were reported in normal pregnancy, and reduced 418 concentrations in pre-eclampsia, where authors hypothesized that Ang-1-7 may function in 419 healthy pregnancy to oppose potentially adverse (vasoconstrictive) effects of Ang II[29, 66]. 420 Similarly, in a recent study, plasma Ang-(1-7) concentrations were elevated throughout 421 pregnancy compared to a non-pregnant control group, and reduced in preeclampsia[28], suggesting a protective effect of ACE2 against hypertension during pregnancy via generation of 422 423 Ang-1-7. In contrast, we report limited detection of Ang-1-7 in NT and HYP patients (using mass 424 spectrometry, which is the gold standard for quantification of biological molecules and a major 425 strength of our study[67, 68]); in samples where Ang-1-7 was detected, concentrations were 426 significantly lower than those reported in other studies via radioimmunoassay[28, 29]. 427 Discrepancies in reported values likely result from different methodologies used for the 428 detection of Ang-1-7, where cross-reactivity in antibody-based assays, (as peptide sequences 429 may only differ by one or two amino acids), may explain artificially high measured 430 concentrations of Ang-1-7[69]. Notably, reliability of ELISA for quantification of angiotensin-(1-7) 431 has recently been called into question[70]). Ang-1-5, a c-terminal metabolite of Ang-1-7, is considered a component of the alternative RAAS[51, 71]. Ang-1-5 was readily detected in our 432 433 study by mass spectrometry, so we used the sum of Ang-1-7 and Ang-1-6 concentrations as an 434 indicator of the alternative RAAS. Concentration of Ang-1-7 + Ang-1-5 did increase over gestation in NT, but not HYP pregnancies. However, concentrations of angiotensin metabolites 435 436 downstream from Ang II, (whether c- or n-terminally degraded), 10-fold less than the 437 concentrations of Ang II and Ang I. This data suggests the main bioactive effector of the RAAS

is Ang II, and that modulatory effects of Ang-1-7 in pregnancy are likely specific to localtissues[72].

440 Our study has several limitations. We did not differentiate among pre-eclampsia and 441 gestational hypertension due to small numbers. Pre-eclampsia, especially, is a heterogenous 442 disease, where some subtypes may result from a different pathophysiology[6], with a different 443 RAAS profile. Also, our study did not control for sodium or volume status, which could affect 444 concentrations of aldosterone and PRA-S. Although previous studies have indicated that 445 sensitivity of renin and aldosterone to salt are blunted in pregnancy[57, 73], differences in salt 446 and aldosterone relationships in pregnancy hypertension versus normotensive are not wellunderstood. 447

448

## 449 **5.** Conclusions

450 In summary, we sought to define prominent features of RAAS activity associated with the development of pregnancy hypertension using a novel methodology for comprehensive 451 452 assessment of the RAAS. Concentrations of PRA-S, angiotensin peptides, and aldosterone 453 were not different among NT and HYP in the first trimester, significantly increased over 454 gestation only in the group that remained NT, and tended to be lower in the third trimester in 455 HYP compared to NT. We conclude that pregnancies that develop HYP are characterized by 456 stalled or waning activation of the RAAS in the second half of pregnancy (accompanied by 457 unchanging levels of angiotensin peptides) and attenuated secretion of aldosterone. Clinical 458 application of this knowledge may inform detection or treatment of pregnancy hypertension or 459 related adverse outcomes.

- 461 **Author contributions.** Study conception and design (JAB, JOB, AS); clinical data collection
- 462 (KV, AS, HH, CC); blood analysis of RAS and interpretation (RS, MP); analysis and
- 463 interpretation of results (RS, MP, AS, JAB, JOB); manuscript preparation (RS).
- 464 **Sources of funding.** The work was supported in part by a grant from the Kentucky BIRCWH
- 465 Program, NIDA 5K12DA035150 (RS) and by the Kentucky Children's Hospital Children's
- 466 Miracle Network Research Fund.
- 467 Institutional Review Board Statement: The study was conducted in accordance with the
- 468 Declaration of Helsinki, and approved by the Institutional Review Board at the University of
- Kentucky. All study procedures/methods were performed in accordance with relevant guidelines
- 470 and regulations.
- 471 **Informed Consent Statement**: Informed consent was obtained from all subjects involved in the
- 472 study.
- 473 **Data availability.** Data may be made available by investigators upon reasonable request to
- 474 corresponding author: <u>robin.shoemaker@uky.edu</u>.
- 475 **Competing interests.** M. Poglitsch is an employee at Attoquant Diagnostics, a company
- 476 developing angiotensin-based biomarkers for hypertension. The other authors report no
- 477 conflicts.

# 478 6. References

479 Wen, T.; Schmidt, C. N.; Sobhani, N. C.; Guglielminotti, J.; Miller, E. C.; Sutton, D.; Lahtermaher, 1. 480 Y.; D'Alton, M. E.; Friedman, A. M., Trends and outcomes for deliveries with hypertensive disorders of pregnancy from 2000 to 2018: A repeated cross-sectional study. BJOG 2022, 129, 481 482 (7), 1050-1060. 483 2. Alexander, B. T.; South, A. M.; August, P.; Bertagnolli, M.; Ferranti, E. P.; Grobe, J. L.; Jones, E. J.; 484 Loria, A. S.; Safdar, B.; Sequeira-Lopez, M. L. S.; American Heart Association Council on the 485 Kidney in Cardiovascular, D.; Council on, C.; Stroke, N.; Council on Cardiovascular, R.; 486 Intervention; Council on, H.; Council on, L.; Cardiometabolic, H., Appraising the Preclinical 487 Evidence of the Role of the Renin-Angiotensin-Aldosterone System in Antenatal Programming of 488 Maternal and Offspring Cardiovascular Health Across the Life Course: Moving the Field Forward: 489 A Scientific Statement From the American Heart Association. Hypertension 2023, 80, (5), e75-490 e89.

491 492 493	3.	Cirillo, P. M.; Cohn, B. A., Pregnancy complications and cardiovascular disease death: 50-year follow-up of the Child Health and Development Studies pregnancy cohort. <i>Circulation</i> <b>2015</b> , 132, (13), 1234-42.
494 495 496	4.	Lo, C. C. W.; Lo, A. C. Q.; Leow, S. H.; Fisher, G.; Corker, B.; Batho, O.; Morris, B.; Chowaniec, M.; Vladutiu, C. J.; Fraser, A.; Oliver-Williams, C., Future Cardiovascular Disease Risk for Women With Gestational Hypertension: A Systematic Review and Meta-Analysis. <i>J Am Heart Assoc</i> <b>2020</b> , 9 (12), c012091
498 499	5.	Rana, S.; Lemoine, E.; Granger, J. P.; Karumanchi, S. A., Preeclampsia: Pathophysiology, Challenges, and Perspectives. <i>Circ Res</i> <b>2019</b> , 124, (7), 1094-1112.
500 501	6.	Society for Maternal-Fetal Medicine . Electronic address, p. s. o., Executive summary: Workshop on Preeclampsia, January 25-26, 2021, cosponsored by the Society for Maternal-Fetal Medicine
502 503 504	7.	and the Preeclampsia Foundation. <i>Am J Obstet Gynecol</i> <b>2021,</b> 225, (3), B2-B7. Wu, C. H.; Mohammadmoradi, S.; Chen, J. Z.; Sawada, H.; Daugherty, A.; Lu, H. S., Renin- Angiotensin System and Cardiovascular Functions. <i>Arterioscler Thromb Vasc Biol</i> <b>2018,</b> 38, (7),
505 506	8.	e108-e116. Irani, R. A.; Xia, Y., The functional role of the renin-angiotensin system in pregnancy and
507 508	9.	preeclampsia. <i>Placenta</i> <b>2008</b> , 29, (9), 763-71. Johns, D. W.; Peach, M. J.; Gomez, R. A.; Inagami, T.; Carey, R. M., Angiotensin II regulates renin
509 510	10.	gene expression. Am J Physiol <b>1990</b> , 259, (6 Pt 2), F882-7. Vickers, C.; Hales, P.; Kaushik, V.; Dick, L.; Gavin, J.; Tang, J.; Godbout, K.; Parsons, T.; Baronas, E.;
511 512 513		human angiotensin-converting enzyme-related carboxypeptidase. <i>J Biol Chem</i> <b>2002,</b> 277, (17), 14838-43
514 515	11.	Ferrario, C. M.; Chappell, M. C.; Tallant, E. A.; Brosnihan, K. B.; Diz, D. I., Counterregulatory actions of angiotensin-(1-7). <i>Hypertension</i> <b>1997</b> , 30, (3 Pt 2), 535-41.
516 517	12.	Allen, A. M.; Zhuo, J.; Mendelsohn, F. A., Localization and function of angiotensin AT1 receptors. <i>Am J Hypertens</i> <b>2000</b> , 13, (1 Pt 2), 31S-38S.
518 519	13.	Forrester, S. J.; Booz, G. W.; Sigmund, C. D.; Coffman, T. M.; Kawai, T.; Rizzo, V.; Scalia, R.; Eguchi, S., Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and
520 521 522	14.	Pathophysiology. <i>Physiol Rev</i> <b>2018</b> , 98, (3), 1627-1738. Montezano, A. C.; Nguyen Dinh Cat, A.; Rios, F. J.; Touyz, R. M., Angiotensin II and vascular injury. <i>Curr Hypertens Rep</i> <b>2014</b> , 16, (6), 431
523 524 525	15.	Minas, J. N.; Thorwald, M. A.; Conte, D.; Vazquez-Medina, J. P.; Nishiyama, A.; Ortiz, R. M., Angiotensin and mineralocorticoid receptor antagonism attenuates cardiac oxidative stress in angiotensin II-infused rate. <i>Clin Exp Pharmacol Physiol</i> <b>2015</b> , <i>4</i> 2, (11), 1178-88
526 527	16.	Binder, C.; Poglitsch, M.; Agibetov, A.; Duca, F.; Zotter-Tufaro, C.; Nitsche, C.; Aschauer, S.; Kammerlander, A. A.; Oeztuerk, B.; Hengstenberg, C.; Mascherbauer, J.; Bonderman, D., Angs
528 529 530	17	(Angiotensins) of the Alternative Renin-Angiotensin System Predict Outcome in Patients With Heart Failure and Preserved Ejection Fraction. <i>Hypertension</i> <b>2019</b> , 74, (2), 285-294. Ramchand L: Patel S. K.; Kearney L. G.; Matalanis, G.; Farouque, O.; Srivastava, P. M.; Burrell
531 532	17.	L. M., Plasma ACE2 Activity Predicts Mortality in Aortic Stenosis and Is Associated With Severe Myocardial Fibrosis. <i>JACC Cardiovasc Imaging</i> <b>2020,</b> 13, (3), 655-664.
533 534 535	18.	Wong, D. W.; Oudit, G. Y.; Reich, H.; Kassiri, Z.; Zhou, J.; Liu, Q. C.; Backx, P. H.; Penninger, J. M.; Herzenberg, A. M.; Scholey, J. W., Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. <i>Am J Pathol</i> <b>2007</b> , 171 (2), 438-51
536 537	19.	Patel, S. K.; Juno, J. A.; Lee, W. S.; Wragg, K. M.; Hogarth, P. M.; Kent, S. J.; Burrell, L. M., Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19
538		pathogenesis and consequences. Eur Respir J <b>2021,</b> 57, (5).

539	20.	Weinberger, M. H.; Kramer, N. J.; Petersen, L. P.; Cleary, R. E.; Young, P. C., Sequential changes
540		in the reninangiotensinaldosterone systems and plasma progesterone concentration in
541		normal and abnormal human pregnancy. <i>Perspect Nephrol Hypertens</i> <b>1976,</b> 5, 263-9.
542	21.	Brown, M. A.: Zammit, V. C.: Mitar, D. A.: Whitworth, J. A., Renin-aldosterone relationships in
543		pregnancy-induced hypertension $\Delta m$ / Hypertens <b>1992</b> 5 (6 Pt 1) 366-71
510	22	Bentley Lewis R : Graves S W : Seely E W. The renin aldosterone response to stimulation and
544	22.	bendey-Lewis, N., Graves, S. W., Seely, E. W., The remn-adosterone response to stimulation and
545	22	Suppression during normal pregnancy. <i>Hypertens Pregnancy</i> <b>2005</b> , 24, (1), 1-16.
546	23.	Verdonk, K.; Visser, W.; Van Den Meiracker, A. H.; Danser, A. H., The renin-anglotensin-
547		aldosterone system in pre-eclampsia: the delicate balance between good and bad. <i>Clin Sci</i>
548		(Lond) <b>2014,</b> 126, (8), 537-44.
549	24.	Jensen, E.; Wood, C.; Keller-Wood, M., The normal increase in adrenal secretion during
550		pregnancy contributes to maternal volume expansion and fetal homeostasis. J Soc Gynecol
551		Investig <b>2002,</b> 9, (6), 362-71.
552	25.	Tsai, Y. L.; Wu, S. J.; Chen, Y. M.; Hsieh, B. S., Changes in renin activity, aldosterone level and
553		electrolytes in pregnancy-induced hypertension. J Formos Med Assoc <b>1993,</b> 92, (6), 514-8.
554	26.	Elsheikh, A.; Creatsas, G.; Mastorakos, G.; Milingos, S.; Loutradis, D.; Michalas, S., The renin-
555		aldosterone system during normal and hypertensive pregnancy. Arch Gynecol Obstet <b>2001</b> , 264.
556		(4). 182-5.
557	27	Zitouni H : Raguema N : Gannoun M B A : Hebert-Stutter M : Zouari L : Maleh W : Faleh R :
558		Letaifa D. B.: Almawi W. V.: Fournier T.: Mahiouh T.: Guibourdenche L. Impact of obesity on
550		the association of active regin and plasma aldosterone concentrations, and aldosterone to regin
555		ratio with procedemocia. Brogganger Hungstons <b>2019</b> , 14, 120, 144
500	20	Tatto with preeclampsia. Preynancy Hypertens <b>2018,</b> 14, 139-144.
561	28.	Tamanna, S.; Clifton, V. L.; Rae, K.; Van Heiden, D. F.; Lumbers, E. R.; Pringle, K. G., Angiotensin
562		Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age. Front
563		Physiol <b>2020,</b> 11, 590787.
564	29.	Merrill, D. C.; Karoly, M.; Chen, K.; Ferrario, C. M.; Brosnihan, K. B., Angiotensin-(1-7) in normal
565		and preeclamptic pregnancy. <i>Endocrine</i> <b>2002,</b> 18, (3), 239-45.
566	30.	Sykes, S. D.; Pringle, K. G.; Zhou, A.; Dekker, G. A.; Roberts, C. T.; Lumbers, E. R.; consortium, S.,
567		Fetal sex and the circulating renin-angiotensin system during early gestation in women who
568		later develop preeclampsia or gestational hypertension. J Hum Hypertens 2014, 28, (2), 133-9.
569	31.	J, J. S.; M, A. B., Renin-angiotensin system in pre-eclampsia: everything old is new again. Obstet
570		Med <b>2012,</b> 5, (4), 147-153.
571	32.	Burrello, J.; Buffolo, F.; Domenig, O.; Tetti, M.; Pecori, A.; Monticone, S.; Poglitsch, M.; Mulatero,
572		P., Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary
573		Aldosteronism. <i>Hypertension</i> <b>2020.</b> 75. (1), 163-172.
574	33	Rinder C · Poglitsch M · Duca E · Rettl R · Dachs T M · Dalos D · Schrutka L · Seirer B · Ligios
575	55.	L C : Canelle C : Eslam R B : Oin H : Hengstenberg C : Bonderman D. Renin Feedback Is an
576		Independent Predictor of Outcome in HEnEE / Dars Med <b>2021</b> 11 (5)
570	24	Dave N. Celiasch C. Wurm P. Nevek L. Strunk C. Guenguesi M. Deglitsch M. Saemann
577	54.	Pavo, N.; Gonasch, G.; Wurn, N.; Novak, J.; Strunk, G.; Gyöngyösi, W.; Pognisch, W.; Saemann,
576		W. D.; Huismann, W., Low- and High-renin Heart Failure Phenotypes with Clinical Implications.
579	25	Clin Chem <b>2018,</b> 64, (3), 597-608.
580	35.	Jha, S.; Taschler, U.; Domenig, U.; Poglitsch, M.; Bourgeois, B.; Pollheimer, M.; Pusch, L. M.;
581		Malovan, G.; Frank, S.; Madl, T.; Gruber, K.; Zimmermann, R.; Macheroux, P., Dipeptidyl
582		peptidase 3 modulates the renin-angiotensin system in mice. <i>J Biol Chem</i> <b>2020</b> , 295, (40), 13711-
583		13723.
584	36.	Wolf, P.; Mayr, J.; Beiglbock, H.; Fellinger, P.; Winhofer, Y.; Poglitsch, M.; Gessl, A.; Kautzky-
585		Willer, A.; Luger, A.; Krebs, M., Identifying a disease-specific renin-angiotensin-aldosterone

586 587		system fingerprint in patients with primary adrenal insufficiency. <i>Eur J Endocrinol</i> <b>2019</b> , 181, (1), 39-44.
588 589	37.	LeFevre, M. L.; Force, U. S. P. S. T., Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement
590		Ann Intern Med <b>2014</b> , 161 (11) 819-26
591	38.	Pickering, T. G.; Hall, J. F.; Appel, L. J.; Falkner, B. F.; Graves, J. W.; Hill, M. N.; Jones, D. H.; Kurtz,
592		T.: Sheps, S. G.: Roccella, F. J.: Council on High Blood Pressure Research, P.: Public Education
593		Subcommittee, A. H. A., Recommendations for blood pressure measurement in humans: an AHA
594		scientific statement from the Council on High Blood Pressure Research Professional and Public
595		Education Subcommittee. J Clin Hypertens (Greenwich) <b>2005,</b> 7, (2), 102-9.
596	39.	Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists'
597		Task Force on Hypertension in Pregnancy. Obstet Gynecol <b>2013</b> , 122, (5), 1122-1131.
598	40.	Haschke, M.; Schuster, M.; Poglitsch, M.; Loibner, H.; Salzberg, M.; Bruggisser, M.; Penninger, J.;
599		Krähenbühl, S., Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-
600		converting enzyme 2 in healthy human subjects. <i>Clin Pharmacokinet</i> <b>2013,</b> 52, (9), 783-92.
601	41.	Guo, Z.; Poglitsch, M.; McWhinney, B. C.; Ungerer, J. P. J.; Ahmed, A. H.; Gordon, R. D.; Wolley,
602		M.; Stowasser, M., Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary
603		Aldosteronism. <i>Clin Chem</i> <b>2020,</b> 66, (3), 483-492.
604	42.	Bernstone, L.; Adaway, J. E.; Keevil, B. G., An LC-MS/MS assay for analysis of equilibrium
605		angiotensin II in human serum. Ann Clin Biochem <b>2021</b> , 45632211008923.
606	43.	Basu, R.; Poglitsch, M.; Yogasundaram, H.; Thomas, J.; Rowe, B. H.; Oudit, G. Y., Roles of
607		Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. J Am Coll Cardiol 2017, 69,
608		(7), 805-819.
609	44.	van Rooyen, J. M.; Poglitsch, M.; Huisman, H. W.; Mels, C.; Kruger, R.; Malan, L.; Botha, S.;
610		Lammertyn, L.; Gafane, L.; Schutte, A. E., Quantification of systemic renin-angiotensin system
611		peptides of hypertensive black and white African men established from the RAS-Fingerprint(R). J
612	a =	Renin Angiotensin Aldosterone Syst <b>2016,</b> 17, (4).
613	45.	van Rooyen, J. M.; Poglitsch, M.; Huisman, H. W.; Gafane-Matemane, L. F.; Breet, Y.; Malan, L., A
614 C15		primary aldosteronism-like phenotype identified with the aldosterone-to-angiotensin II ratio in
615	10	black men: the SABPA study. <i>Cardiovasc J Afr</i> <b>2020</b> , 31, (3), 130-135.
010 617	40.	Galarie-Matemarie, L. F.; Mokae, N. L.; Breet, F.; Pogrisch, M.; Schutte, A. E., Associations of
619		volume adults: the African DPEDICT study. Hungstons Pac <b>2021</b> , 44, (4), 425, 445
610	17	Wang K Basu R Poglitsch M Bakal I A Oudit G V Elevated Angiotensin 1.7/Angiotensin
620	47.	Il Ratio Predicts Favorable Outcomes in Patients With Heart Failure <i>Circ Heart Fail</i> <b>2020</b> 13 (7)
621		
622	48.	Reindl-Schwaighofer, R.: Hödlmoser, S.: Eskandary, F.: Poglitsch, M.: Bonderman, D.: Strassl, R.:
623		Aberle, J. H.: Oberbauer, R.: Zoufaly, A.: Hecking, M., Angiotensin-Converting Enzyme 2 (ACE2)
624		Elevation in Severe COVID-19. Am J Respir Crit Care Med <b>2021</b> .
625	49.	Krenn, K.; Hobart, P.; Poglitsch, M.; Croize, A.; Ullrich, R., Equilibrium Angiotensin Metabolite
626		Profiling in Patients with Acute Respiratory Distress Syndrome Indicates Angiotensin-Converting
627		Enzyme Inhibition. Am J Respir Crit Care Med <b>2020,</b> 202, (10), 1468-1471.
628	50.	Antlanger, M.; Bernhofer, S.; Kovarik, J. J.; Kopecky, C.; Kaltenecker, C. C.; Domenig, O.;
629		Poglitsch, M.; Saemann, M. D., Effects of direct renin inhibition versus angiotensin II receptor
630		blockade on angiotensin profiles in non-diabetic chronic kidney disease. Ann Med 2017, 49, (6),
631		525-533.
632	51.	Hartl, L.; Rumpf, B.; Domenig, O.; Simbrunner, B.; Paternostro, R.; Jachs, M.; Poglitsch, M.;
633		Marculescu, R.; Trauner, M.; Reindl-Schwaighofer, R.; Hecking, M.; Mandorfer, M.; Reiberger, T.,

634		The systemic and hepatic alternative renin-angiotensin system is activated in liver cirrhosis,
635		linked to endothelial dysfunction and inflammation. <i>Sci Rep</i> <b>2023</b> , 13, (1), 953.
636	52.	Langer, B.; Grima, M.; Coquard, C.; Bader, A. M.; Schlaeder, G.; Imbs, J. L., Plasma active renin,
637		angiotensin I, and angiotensin II during pregnancy and in preeclampsia. Obstet Gynecol 1998, 91,
638		(2), 196-202.
639	53.	Wiegel, R. E.; Jan Danser, A. H.; Steegers-Theunissen, R. P. M.; Laven, J. S. E.; Willemsen, S. P.;
640		Baker, V. L.; Steegers, E. A. P.; von Versen-Hoynck, F., Determinants of Maternal Renin-
641		Angiotensin-Aldosterone-System Activation in Early Pregnancy: Insights From 2 Cohorts. J Clin
642		Endocrinol Metab <b>2020,</b> 105, (11).
643	54.	Salas, S. P.; Marshall, G.; Gutierrez, B. L.; Rosso, P., Time course of maternal plasma volume and
644		hormonal changes in women with preeclampsia or fetal growth restriction. Hypertension 2006,
645		47, (2), 203-8.
646	55.	Malha, L.; Sison, C. P.; Helseth, G.; Sealey, J. E.; August, P., Renin-Angiotensin-Aldosterone
647		Profiles in Pregnant Women With Chronic Hypertension. <i>Hypertension</i> <b>2018</b> , 72, (2), 417-424.
648	56.	Satou, R.; Kobori, H.; Katsurada, A.; Miyata, K.; Navar, L. G., Quantification of intact plasma AGT
649		consisting of oxidized and reduced conformations using a modified ELISA. Am J Physiol Renal
650		Physiol <b>2016,</b> 311, (6), F1211-F1216.
651	57.	Brown, M. A.; Nicholson, E.; Gallery, E. D., Sodium-renin-aldosterone relations in normal and
652		hypertensive pregnancy. Br J Obstet Gynaecol <b>1988,</b> 95, (12), 1237-46.
653	58.	Mishra, J. S.; Gopalakrishnan, K.; Kumar, S., Pregnancy upregulates angiotensin type 2 receptor
654		expression and increases blood flow in uterine arteries of rats. <i>Biol Reprod</i> 2018, 99, (5), 1091-
655		1099.
656	59.	Satou, R.; Penrose, H.; Navar, L. G., Inflammation as a Regulator of the Renin-Angiotensin
657		System and Blood Pressure. Curr Hypertens Rep <b>2018</b> , 20, (12), 100.
658	60.	Li, X. C.; Leite, A. P. O.; Zheng, X.; Zhao, C.; Chen, X.; Zhang, L.; Zhou, X.; Rubera, I.; Tauc, M.;
659		Zhuo, J. L., Proximal Tubule-Specific Deletion of Angiotensin II Type 1a Receptors in the Kidney
660		Attenuates Circulating and Intratubular Angiotensin II-Induced Hypertension in PT-Agtr1a(-/-)
661		Mice. Hypertension <b>2021,</b> 77, (4), 1285-1298.
662	61.	Brown, M. A.; Thou, S. T.; Whitworth, J. A., Stimulation of aldosterone by ACTH in normal and
663		hypertensive pregnancy. Am J Hypertens <b>1995,</b> 8, (3), 260-7.
664	62.	Gennari-Moser, C.; Khankin, E. V.; Escher, G.; Burkhard, F.; Frey, B. M.; Karumanchi, S. A.; Frey,
665		F. J.; Mohaupt, M. G., Vascular endothelial growth factor-A and aldosterone: relevance to
666		normal pregnancy and preeclampsia. <i>Hypertension</i> 2013, 61, (5), 1111-7.
667	63.	Siddiqui, A. H.; Irani, R. A.; Zhang, W.; Wang, W.; Blackwell, S. C.; Kellems, R. E.; Xia, Y.,
668		Angiotensin receptor agonistic autoantibody-mediated soluble fms-like tyrosine kinase-1
669		induction contributes to impaired adrenal vasculature and decreased aldosterone production in
670		preeclampsia. Hypertension <b>2013,</b> 61, (2), 472-9.
671	64.	Marino, G. I.; Kotsias, B. A., Expression of the epithelial sodium channel sensitive to amiloride
672		(ENaC) in normal and preeclamptic human placenta. <i>Placenta</i> <b>2013,</b> 34, (2), 197-200.
673	65.	Escher, G.; Cristiano, M.; Causevic, M.; Baumann, M.; Frey, F. J.; Surbek, D.; Mohaupt, M. G.,
674		High aldosterone-to-renin variants of CYP11B2 and pregnancy outcome. Nephrol Dial Transplant
675		<b>2009,</b> 24, (6), 1870-5.
676	66.	Brosnihan, K. B.; Neves, L. A.; Anton, L.; Joyner, J.; Valdes, G.; Merrill, D. C., Enhanced expression
677		of Ang-(1-7) during pregnancy. <i>Braz J Med Biol Res</i> <b>2004,</b> 37, (8), 1255-62.
678	67.	Rehan, M.; Raizman, J. E.; Cavalier, E.; Don-Wauchope, A. C.; Holmes, D. T., Laboratory
679		challenges in primary aldosteronism screening and diagnosis. Clin Biochem 2015, 48, (6), 377-87.
680	68.	Webster, L. M.; Gill, C.; Seed, P. T.; Bramham, K.; Wiesender, C.; Nelson-Piercy, C.; Myers, J. E.;
681		Chappell, L. C., Chronic hypertension in pregnancy: impact of ethnicity and superimposed

682 preeclampsia on placental, endothelial, and renal biomarkers. *Am J Physiol Regul Integr Comp* 683 *Physiol* **2018**, 315, (1), R36-R47.

- 684 69. Chappell, M. C., Biochemical evaluation of the renin-angiotensin system: the good, bad, and 685 absolute? *Am J Physiol Heart Circ Physiol* **2016**, 310, (2), H137-52.
- Chappell, M. C.; Pirro, N. T.; South, A. M.; Gwathmey, T. M., Concerns on the Specificity of
  Commercial ELISAs for the Measurement of Angiotensin (1-7) and Angiotensin II in Human
  Plasma. *Hypertension* 2021, 77, (3), e29-e31.
- 68971.Park, B. M.; Li, W.; Kim, S. H., Cardio-protective effects of angiotensin-(1-5) via mas receptor in690rats against ischemic-perfusion injury. *Peptides* **2021**, 139, 170516.
- 72. Delforce, S. J.; Lumbers, E. R.; Ellery, S. J.; Murthi, P.; Pringle, K. G., Dysregulation of the
  placental renin-angiotensin system in human fetal growth restriction. *Reproduction* 2019, 158,
  (3), 237-245.
- 694 73. Gennari-Moser, C.; Escher, G.; Kramer, S.; Dick, B.; Eisele, N.; Baumann, M.; Raio, L.; Frey, F. J.;
  695 Surbek, D.; Mohaupt, M. G., Normotensive blood pressure in pregnancy: the role of salt and
  696 aldosterone. *Hypertension* **2014**, 63, (2), 362-8.